<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD02200000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>O76074</UniProt_ID>
  <Seq_Length>875</Seq_Length>
  <Molecule_Weight>100013</Molecule_Weight>
  <KEGG_ID>hsa:8654</KEGG_ID>
  <Orthology_ID>K13762</Orthology_ID>
  <Function_Summary>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP.</Function_Summary>
  <Catalytic_Mechanism>Guanosine 3',5'-cyclic phosphate + H(2)O = guanosine 5'-phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF01590:GAF@@PF00233:PDEase_I</Pfam_ID>
  <Allosteric_Activator_Count>3</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>2</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>1</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>PDE5</Alias>
      <Alias>CGMP-binding cGMP-specific phosphodiesterase</Alias>
      <Alias>CGB-PDE</Alias>
      <Alias>CGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with cGMP, the nucleotide cyclic GMP (guanosine 3',5'-cyclophosphate).</Detail>
      <Keyword>CGMP binding</Keyword>
      <Ontology_ID>GO:0030553</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic.</Detail>
      <Keyword>Catalytic activity</Keyword>
      <Ontology_ID>GO:0003824</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: guanosine 3',5'-cyclic phosphate + H2O = guanosine 5'-phosphate.</Detail>
      <Keyword>3',5'-cyclic-GMP phosphodiesterase activity</Keyword>
      <Ontology_ID>GO:0047555</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>181</Position>
      <Original>Ser</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>93</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of cyclic GMP, guanosine 3',5'-phosphate.</Detail>
      <Keyword>CGMP catabolic process</Keyword>
      <Ontology_ID>GO:0046069</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>102</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAERVHTIPVCKEGIRGHTESCSCPLQQSPRADNSVPGTPTRKISASEFDRPLRPIVVKDSEGTVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLISADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPLNIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDEKDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIISFMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTMEPLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGKVKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETRELQSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWILSVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGVNNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAILATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAELVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCFPLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN</Protein_Seq>
    <DNA_Seq>GCGGCCGCGCTCCGGCCGCTTTGTCGAAAGCCGGCCCGACTGGAGCAGGACGAAGGGGGAGGGTCTCGAGGCCGAGTCCTGTTCTTCTGAGGGACGGACCCCAGCTGGGGTGGAAAAGCAGTACCAGAGAGCCTCCGAGGCGCGCGGTGCCAACCATGGAGCGGGCCGGCCCCAGCTTCGGGCAGCAGCGACAGCAGCAGCAGCCCCAGCAGCAGAAGCAGCAGCAGAGGGATCAGGACTCGGTCGAAGCATGGCTGGACGATCACTGGGACTTTACCTTCTCATACTTTGTTAGAAAAGCCACCAGAGAAATGGTCAATGCATGGTTTGCTGAGAGAGTTCACACCATCCCTGTGTGCAAGGAAGGTATCAGAGGCCACACCGAATCTTGCTCTTGTCCCTTGCAGCAGAGTCCTCGTGCAGATAACAGTGTCCCTGGAACACCAACCAGGAAAATCTCTGCCTCTGAATTTGACCGGCCTCTTAGACCCATTGTTGTCAAGGATTCTGAGGGAACTGTGAGCTTCCTCTCTGACTCAGAAAAGAAGGAACAGATGCCTCTAACCCCTCCAAGGTTTGATCATGATGAAGGGGACCAGTGCTCAAGACTCTTGGAATTAGTGAAGGATATTTCTAGTCATTTGGATGTCACAGCCTTATGTCACAAAATTTTCTTGCATATCCATGGACTGATATCTGCTGACCGCTATTCCCTGTTCCTTGTCTGTGAAGACAGCTCCAATGACAAGTTTCTTATCAGCCGCCTCTTTGATGTTGCTGAAGGTTCAACACTGGAAGAAGTTTCAAATAACTGTATCCGCTTAGAATGGAACAAAGGCATTGTGGGACATGTGGCAGCGCTTGGTGAGCCCTTGAACATCAAAGATGCATATGAGGATCCTCGGTTCAATGCAGAAGTTGACCAAATTACAGGCTACAAGACACAAAGCATTCTTTGTATGCCAATTAAGAATCATAGGGAAGAGGTTGTTGGTGTAGCCCAGGCCATCAACAAGAAATCAGGAAACGGTGGGACATTTACTGAAAAAGATGAAAAGGACTTTGCTGCTTATTTGGCATTTTGTGGTATTGTTCTTCATAATGCTCAGCTCTATGAGACTTCACTGCTGGAGAACAAGAGAAATCAGGTGCTGCTTGACCTTGCTAGTTTAATTTTTGAAGAACAACAATCATTAGAAGTAATTTTGAAGAAAATAGCTGCCACTATTATCTCTTTCATGCAAGTGCAGAAATGCACCATTTTCATAGTGGATGAAGATTGCTCCGATTCTTTTTCTAGTGTGTTTCACATGGAGTGTGAGGAATTAGAAAAATCATCTGATACATTAACAAGGGAACATGATGCAAACAAAATCAATTACATGTATGCTCAGTATGTCAAAAATACTATGGAACCACTTAATATCCCAGATGTCAGTAAGGATAAAAGATTTCCCTGGACAACTGAAAATACAGGAAATGTAAACCAGCAGTGCATTAGAAGTTTGCTTTGTACACCTATAAAAAATGGAAAGAAGAATAAAGTTATAGGGGTTTGCCAACTTGTTAATAAGATGGAGGAGAATACTGGCAAGGTTAAGCCTTTCAACCGAAATGACGAACAGTTTCTGGAAGCTTTTGTCATCTTTTGTGGCTTGGGGATCCAGAACACGCAGATGTATGAAGCAGTGGAGAGAGCCATGGCCAAGCAAATGGTCACATTGGAGGTTCTGTCGTATCATGCTTCAGCAGCAGAGGAAGAAACAAGAGAGCTACAGTCGTTAGCGGCTGCTGTGGTGCCATCTGCCCAGACCCTTAAAATTACTGACTTTAGCTTCAGTGACTTTGAGCTGTCTGATCTGGAAACAGCACTGTGTACAATTCGGATGTTTACTGACCTCAACCTTGTGCAGAACTTCCAGATGAAACATGAGGTTCTTTGCAGATGGATTTTAAGTGTTAAGAAGAATTATCGGAAGAATGTTGCCTATCATAATTGGAGACATGCCTTTAATACAGCTCAGTGCATGTTTGCTGCTCTAAAAGCAGGCAAAATTCAGAACAAGCTGACTGACCTGGAGATACTTGCATTGCTGATTGCTGCACTAAGCCACGATTTGGATCACCGTGGTGTGAATAACTCTTACATACAGCGAAGTGAACATCCACTTGCCCAGCTTTACTGCCATTCAATCATGGAACACCATCATTTTGACCAGTGCCTGATGATTCTTAATAGTCCAGGCAATCAGATTCTCAGTGGCCTCTCCATTGAAGAATATAAGACCACGTTGAAAATAATCAAGCAAGCTATTTTAGCTACAGACCTAGCACTGTACATTAAGAGGCGAGGAGAATTTTTTGAACTTATAAGAAAAAATCAATTCAATTTGGAAGATCCTCATCAAAAGGAGTTGTTTTTGGCAATGCTGATGACAGCTTGTGATCTTTCTGCAATTACAAAACCCTGGCCTATTCAACAACGGATAGCAGAACTTGTAGCAACTGAATTTTTTGATCAAGGAGACAGAGAGAGAAAAGAACTCAACATAGAACCCACTGATCTAATGAACAGGGAGAAGAAAAACAAAATCCCAAGTATGCAAGTTGGGTTCATAGATGCCATCTGCTTGCAACTGTATGAGGCCCTGACCCACGTGTCAGAGGACTGTTTCCCTTTGCTAGATGGCTGCAGAAAGAACAGGCAGAAATGGCAGGCCCTTGCAGAACAGCAGGAGAAGATGCTGATTAATGGGGAAAGCGGCCAGGCCAAGCGGAACTGAGTGGCCTATTTCATGCAGAGTTGAAGTTTACAGAGATGGTGTGTTCTGCAATATGCCTAGTTTCTTACACACTGTCTGTATAGTGTCTGTATTTGGTATATACTTTGCCACTGCTGTATTTTTATTTTTGCACAACTTTTGAGAGTATAGCATGAATGTTTTTAGAGGACTATTACATATTTTTTGTATATTTGTTTTATGCTACTGAACTGAAAGGATCAACAACATCCACTGTTAGCACATTGATAAAAGCATTGTTTGTGATATTTCGTGTACTGCAAAGTGTATGCAGTATTCTTGCACTGAGGTTTTTTTGCTTGGGG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Aortic smooth muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Brain</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Pancreas</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Placenta</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <Gene>
    <Gene_Name>PDE5A</Gene_Name>
    <Gene_Alias>PDE5</Gene_Alias>
    <Gene_ID>8654</Gene_ID>
    <Genbank_ACCN>NM_001083</Genbank_ACCN>
    <Protein_ACCN>NP_001074</Protein_ACCN>
    <HGNC_ID>8784</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/8654</Gene_URL>
    <UCSC_ID>uc003idg.3</UCSC_ID>
    <EMBL_ID>ENSG00000138735</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Arteritic Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Arteritic Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ART110</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arteritic_anterior_ischemic_optic_neuropathy?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transient Global Amnesia</Disease_Name>
      <Disease_Detail>Transient Global Amnesia</Disease_Detail>
      <Disease_DB>TRN012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transient_global_amnesia?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Non-Arteritic Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Non-Arteritic Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>NNR007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/non_arteritic_anterior_ischemic_optic_neuropathy?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Impotence</Disease_Name>
      <Disease_Detail>Impotence</Disease_Detail>
      <Disease_DB>IMP005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/impotence?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ISC002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ischemic_optic_neuropathy?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Premature Ejaculation</Disease_Name>
      <Disease_Detail>Premature Ejaculation</Disease_Detail>
      <Disease_DB>PRM003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/premature_ejaculation?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Priapism</Disease_Name>
      <Disease_Detail>Priapism</Disease_Detail>
      <Disease_DB>PRP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/priapism?search=PDE5A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ANT058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anterior_ischemic_optic_neuropathy?search=PDE5A#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafil</PDB_Title>
      <PDB_ID>3B2R</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3B2R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 5-METHYL-7-PROPYLIMIDAZO
[5,1-F][1,2,4]TRIAZIN- 4(1H)-ONE</Ligand_Name>
      <PubMed_Title>Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.</PubMed_Title>
      <Author>Wang H, et al.</Author>
      <Journal>Mol Pharmacol. 2008 Jan;73(1):104-10.</Journal>
      <PubMed_ID>17959709</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Human Phosphodiesterase 5 complexed with Sildenafil(Viagra)</PDB_Title>
      <PDB_ID>1UDT</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1UDT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 1-METHYL-3-PROPYL
-1H,6H,7H-PYRAZOLO[4,3-D]PYRIMIDIN- 7-ONE</Ligand_Name>
      <PubMed_Title>Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.</PubMed_Title>
      <Author>Sung BJ, et al.</Author>
      <Journal>Nature. 2003 Sep 4;425(6953):98-102.</Journal>
      <PubMed_ID>12955149</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor</PDB_Title>
      <PDB_ID>3BJC</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3BJC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo[4,3-d]pyrimidin-5
-yl)thiophene- 2-sulfonamide</Ligand_Name>
      <PubMed_Title>An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.</PubMed_Title>
      <Author>Chen G, et al.</Author>
      <Journal>Biochem Pharmacol. 2008 May 1;75(9):1717-28.</Journal>
      <PubMed_ID>18346713</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PDE5 in complex with sildenafil</PDB_Title>
      <PDB_ID>2H42</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore.do?structureId=2H42</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 1-METHYL-3-PROPYL
-1H,6H,7H-PYRAZOLO[4,3-D]PYRIMIDIN- 7-ONE</Ligand_Name>
      <PubMed_Title>Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.</PubMed_Title>
      <Author>Wang H, et al.</Author>
      <Journal>J Biol Chem. 2006 Jul 28;281(30):21469-79.</Journal>
      <PubMed_ID>16735511</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMP</PDB_Title>
      <PDB_ID>1T9S</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1T9S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>GUANOSINE-5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.</PubMed_Title>
      <Author>Zhang KY, et al.</Author>
      <Journal>Mol Cell. 2004 Jul 23;15(2):279-86.</Journal>
      <PubMed_ID>15260978</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PDE5A1-IBMX</PDB_Title>
      <PDB_ID>1RKP</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1RKP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-ISOBUTYL-1-METHYLXANTHINE</Ligand_Name>
      <PubMed_Title>Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.</PubMed_Title>
      <Author>Huai Q, et al.</Author>
      <Journal>J Biol Chem. 2004 Mar 26;279(13):13095-101.</Journal>
      <PubMed_ID>14668322</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Human Phosphodiesterase 5 complexed with tadalafil(Cialis)</PDB_Title>
      <PDB_ID>1UDU</PDB_ID>
      <Resolution>2.83</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1UDU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-BENZO[1,3]DIOXOL-5-YL-2-METHYL-2,3,6,7,12,12A- HEXAHYDRO-PYRAZINO
[1',2':1,6]PYRIDO[3,4-B]INDOLE- 1,4-DIONE</Ligand_Name>
      <PubMed_Title>Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.</PubMed_Title>
      <Author>Sung BJ, et al.</Author>
      <Journal>Nature. 2003 Sep 4;425(6953):98-102.</Journal>
      <PubMed_ID>12955149</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF N2 SUBSTITUTED PYRAZOLO PYRIMIDINONES-A FLIPPED BINDING MODE IN PDE5</PDB_Title>
      <PDB_ID>2CHM</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2CHM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-[2-(BUT-3-EN-1-YLOXY)-5-(1-HYDROXYVINYL)PYRIDIN- 3-YL]-3-ETHYL-2-(1
-ETHYLAZETIDIN-3-YL)-1,2,6,7A- TETRAHYDRO-7H-PYRAZOLO[4,3-D]PYRIMIDIN-7- ONE $ 2-(N-MORPHOLINO)-ETHANESULFONIC ACID</Ligand_Name>
      <PubMed_Title>A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.</PubMed_Title>
      <Author>Allerton CM, et al.</Author>
      <Journal>J Med Chem. 2006 Jun 15;49(12):3581-94.</Journal>
      <PubMed_ID>16759100</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Identification, Synthesis, and SAR of Amino Substituted Pyrido[3,2b]pryaziones as Potent and Selective PDE5 Inhibitors</PDB_Title>
      <PDB_ID>3HDZ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3HDZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-amino-1-butyl-7-phenyl-1,6-naphthyridin- 4(1H)-one</Ligand_Name>
      <PubMed_Title>Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.</PubMed_Title>
      <Author>Owen DR, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Aug 1;19(15):4088-91.</Journal>
      <PubMed_ID>19540112</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafil</PDB_Title>
      <PDB_ID>1TBF</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1TBF</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02200004</ASD_Ligand>
      <Ligand_Name>5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 1-METHYL-3-PROPYL
-1H,6H,7H-PYRAZOLO[4,3-D]PYRIMIDIN- 7-ONE</Ligand_Name>
      <PubMed_Title>A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.</PubMed_Title>
      <Author>Zhang KY, et al.</Author>
      <Journal>Mol Cell. 2004 Jul 23;15(2):279-86.</Journal>
      <PubMed_ID>15260978</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PDE5A1 in complex with icarisid II</PDB_Title>
      <PDB_ID>2H44</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore.do?structureId=2H44</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5,7-DIHYDROXY-2-(4-METHOXYPHENYL)-8-(3-METHYLBUTYL)- 4-OXO-4H-CHROMEN-3-YL 6
-DEOXY-ALPHA-L-MANNOPYRANOSIDE</Ligand_Name>
      <PubMed_Title>Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.</PubMed_Title>
      <Author>Wang H, et al.</Author>
      <Journal>J Biol Chem. 2006 Jul 28;281(30):21469-79.</Journal>
      <PubMed_ID>16735511</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafil</PDB_Title>
      <PDB_ID>3JWQ</PDB_ID>
      <Resolution>2.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3JWQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 1-METHYL-3-PROPYL
-1H,6H,7H-PYRAZOLO[4,3-D]PYRIMIDIN- 7-ONE</Ligand_Name>
      <PubMed_Title>Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.</PubMed_Title>
      <Author>Barren B, et al.</Author>
      <Journal>EMBO J. 2009 Nov 18;28(22):3613-22.</Journal>
      <PubMed_ID>19798052</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafil</PDB_Title>
      <PDB_ID>1XP0</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1XP0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 5-METHYL-7-PROPYLIMIDAZO
[5,1-F][1,2,4]TRIAZIN- 4(1H)-ONE</Ligand_Name>
      <PubMed_Title>Structural basis for the activity of drugs that inhibit phosphodiesterases.</PubMed_Title>
      <Author>Card GL, et al.</Author>
      <Journal>Structure. 2004 Dec;12(12):2233-47.</Journal>
      <PubMed_ID>15576036</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Human Phosphodiesterase 5 complexed with Vardenafil(Levitra)</PDB_Title>
      <PDB_ID>1UHO</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1UHO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}- 5-METHYL-7-PROPYLIMIDAZO
[5,1-F][1,2,4]TRIAZIN- 4(1H)-ONE</Ligand_Name>
      <PubMed_Title>Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.</PubMed_Title>
      <Author>Sung BJ, et al.</Author>
      <Journal>Nature. 2003 Sep 4;425(6953):98-102.</Journal>
      <PubMed_ID>12955149</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine (IBMX) and PDE6 gamma-subunit inhibitory peptide 70-87.</PDB_Title>
      <PDB_ID>3JWR</PDB_ID>
      <Resolution>2.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore.do?structureId=3JWR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-ISOBUTYL-1-METHYLXANTHINE</Ligand_Name>
      <PubMed_Title>Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.</PubMed_Title>
      <Author>Barren B, et al.</Author>
      <Journal>EMBO J. 2009 Nov 18;28(22):3613-22.</Journal>
      <PubMed_ID>19798052</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the catalytic domain of unliganded PDE5</PDB_Title>
      <PDB_ID>2H40</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2H40</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.</PubMed_Title>
      <Author>Wang H, et al.</Author>
      <Journal>J Biol Chem. 2006 Jul 28;281(30):21469-79.</Journal>
      <PubMed_ID>16735511</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Catalytic Domain Of Human Phosphodiesterase 5A</PDB_Title>
      <PDB_ID>1T9R</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1T9R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>CITRIC ACID</Ligand_Name>
      <PubMed_Title>A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.</PubMed_Title>
      <Author>Zhang KY, et al.</Author>
      <Journal>Mol Cell. 2004 Jul 23;15(2):279-86.</Journal>
      <PubMed_ID>15260978</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Investigation of Aminopyridiopyrazinones as PDE5 Inhibitors: Evaluation of Modifications to the Central Ring System.</PDB_Title>
      <PDB_ID>3HC8</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3HC8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(6-methoxypyridin-3-yl)-2-[(2-morpholin- 4-ylethyl)amino]-4-(2
-propoxyethyl)pyrido[2,3- b]pyrazin-3(4H)-one</Ligand_Name>
      <PubMed_Title>Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.</PubMed_Title>
      <Author>Hughes RO, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Aug 1;19(15):4092-6.</Journal>
      <PubMed_ID>19539468</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafil</PDB_Title>
      <PDB_ID>1XOZ</PDB_ID>
      <Resolution>1.37</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1XOZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-BENZO[1,3]DIOXOL-5-YL-2-METHYL-2,3,6,7,12,12A- HEXAHYDRO-PYRAZINO
[1',2':1,6]PYRIDO[3,4-B]INDOLE- 1,4-DIONE</Ligand_Name>
      <PubMed_Title>Structural basis for the activity of drugs that inhibit phosphodiesterases.</PubMed_Title>
      <Author>Card GL, et al.</Author>
      <Journal>Structure. 2004 Dec;12(12):2233-47.</Journal>
      <PubMed_ID>15576036</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04022</Pathway_ID>
      <Pathway_Title>cGMP-PKG signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00230</Pathway_ID>
      <Pathway_Title>Purine metabolism</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Nucleotide metabolism</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.bjb.b.c.d.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/2h44</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Corbin JD, et al. Cell.Signal. 2009,21(12):1768-1774.</Site_Reference>
      <Site_Type>Feedback inhibition allostery</Site_Type>
      <PubMed_ID>19665054</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.1.4.35</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/1/4/35.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00480001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00560005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02200001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02200002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02200004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09090001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>